✨ Free AI Report
IDEAYA Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research IDEAYA Biosciences, Inc.
Company Research

IDEAYA Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

IDEAYA Biosciences, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Well-capitalized precision oncology biotech with differentiated ADC/synthetic lethality pipeline targeting high unmet needs and clear regulatory pathway visibility. The company has approximately $1.1 billion in cash and marketable securities as of September 30, 2025, expected to fund its operating plan into 2030. Recent milestones include first-patient enrollment in Phase.

What is IDEAYA Biosciences, Inc.'s industry? IDEAYA Biosciences, Inc. (ideayabio.com) operates in Precision Medicine Oncology / Biotech. AskCyborg classifies IDEAYA Biosciences, Inc. under Precision Medicine Oncology / Biotech in its company registry.

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural...

7/ 10Strong

Cyborg Score thesis

Well-capitalized precision oncology biotech with differentiated ADC/synthetic lethality pipeline targeting high unmet needs and...

Read the full analyst-debate transcript →
Industry Precision Medicine Oncology / Biotech
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest IDEAYA Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for IDEAYA Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for IDEAYA Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
IDEAYA Biosciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

IDEAYA Biosciences, Inc. Overview

Pro stress-test →

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology and bioinformatics with translational biomarker capabilities. The company has built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications.

Strategic Profile

Pro stress-test →

2025 marked a year of execution with broad pipeline advancement and commercial readiness activities for darovasertib, supported by a deep pipeline and cash runway into 2030 addressing multiple indications with high unmet need including uveal melanoma, small cell lung cancer, neuroendocrine cancer, breast cancer, and MTAP-deleted cancers. In 2026, the company plans to advance four registrational trials, including IDE849 (DLL3 TOP1 ADC) in neuroendocrine cancer and darovasertib in uveal melanoma, a poorest prognosis oncology indication where the majority of patients have no available FDA approved therapies.

Competitive Landscape

Pro stress-test →

IDEAYA focuses on synthetic lethality and ADC-based approaches for molecularly defined solid tumors, competing within the broader precision oncology and ADC therapeutic spaces. The company differentiates through its dual-target bispecific ADC platform and focus on difficult-to-treat cancers like uveal melanoma, positioning it against both large pharma oncology divisions and specialized biotech ADC developers.

Industry Context

IDEAYA Biosciences, Inc. operates in Precision Medicine Oncology / Biotech.

Key facts

Headquarters: South San Francisco, United States

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on IDEAYA Biosciences, Inc..

  • OptimUM-02 trial topline PFS data for darovasertib/crizotinib combination in metastatic uveal melanoma expected in Q1 2026, a key near-term catalyst.
  • IDE034 is the company's second proprietary TOP1 ADC, designed to be internalized only when target antigens are co-expressed on same tumor cell, enhancing selectivity and tolerability relative to monovalent antibody formats.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026First patient enrolled in Phase 1 trial of IDE034, potential first-in-class B7H3/PTK7 bispecific TOP1 ADC
  • Feb 2026New Chief Development Officer appointment and inducement stock option grants for three newly hired employees
  • +2 moreTrack every material event for IDEAYA Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when IDEAYA Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ADC/Targeted Oncology TherapiesLeading ADC developer with multiple approved therapies→Synthetic Lethality PlatformsMetabolic synthetic lethality focused oncology company→Uveal Melanoma TherapiesCo-developing darovasertib for uveal melanoma globally→

Compare IDEAYA Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

IDEAYA Biosciences, Inc. operates in Precision Medicine Oncology / Biotech. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Medicine Oncology / Biotech research →
NEW · MCP server

Ask your AI assistant about IDEAYA Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare IDEAYA Biosciences, Inc. and its top competitor on Cyborg Score”
“What did IDEAYA Biosciences, Inc. do this quarter?”
“Is IDEAYA Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does IDEAYA Biosciences, Inc. do?+
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural...
What is IDEAYA Biosciences, Inc.'s Cyborg Score?+
IDEAYA Biosciences, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are IDEAYA Biosciences, Inc.'s main competitors?+
Named competitors include ADC/Targeted Oncology Therapies, Synthetic Lethality Platforms, Uveal Melanoma Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full IDEAYA Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the IDEAYA Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track IDEAYA Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.